Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2022

Supplementary Information

Trans selective cyclization of alpha-bromocarboxamides

and E/Z-mixed internal olefin catalyzed by a Fe salt

Yusei Nakashima, Shinya Ishimaru, Takashi Nishikata* Graduate School of Science and Engineering, Yamaguchi University 2-16-1 Tokiwadai, Ube, Yamaguchi, 755-8611, Japan

S2
S10
S19
S22

1. General information

All reactions were carried out under nitrogen (99.95%) atmosphere. For TLC analyses precoated Kieselgel 60 F254 plates (Merck, 0.25 mm thick) were used; for column chromatography Silica *Flash*® P60 (SiliCycle, 40-63 µm) was used. Visualization was accomplished by UV light (254 nm), ¹H and ¹³C NMR spectra were obtained using a JEOL 500 MHz NMR spectrometer. Chemical shifts for ¹H NMR were described in parts per million (chloroform as an internal standard δ = 7.26) in CDCl₃, unless otherwise noted. Chemical shifts for ¹³C NMR were expressed in parts per million in CDCl₃ as an internal standard (δ = 77.16), unless otherwise noted. High resolution mass analyses were obtained using an ACQUITY UPLC/ TOF-MS for EI. Anhydrous solvents were purchased from Kanto Chemical Co., Ltd. Other chemicals were purchased from TCI, Sigma and Wako and used after distillation or from the bottles (solid). Iron chloride was purchased from Sigma Co., Ltd.

Starting Materials



Figure S1. Starting materials.

Reported materials: 1a, 1i, 1k, 1l, 2a, 2b, 2c, 2d, 2e, 2g

1a, 2a, 2b, 2c, 2d, 2e, 2g: Nakashima, Y.; Matsumoto, J.; Nishikata, T. ACS Catal. 2021, 11, 11526-11531.

1i: Cavicchioni, G. Tetrahedron Letters 1987, 28, 2427-2430.

1k: Tomasik, C. A.; Mitra, A.; West, R. Organometallics 2009, 28, 378-381.

11: Miwa, N.; Yamane, Y.; Nishikata, T. Chem. Lett. 2017, 46, 563-565.

All 2-bromocarbonyls (1) were synthesized from reported procedures: Murata, Y.; Takeuchi, K.; Nishikata, T. *Tetrahedron* **2019**, *75*, 2726-2736.

2-bromo-2-methyl-N-phenylpropanamide (1a)



¹H NMR (CDCl₃) δ : 2.06 (s, 6H), 7.15 (t, *J* = 7.4 Hz, 1H), 7.36 (t, *J* = 8.0 Hz, 2H), 7.55 (d, *J* = 8.0 Hz, 2H), 8.46 (s, 1H). ¹³C NMR (CDCl₃) δ : 32.7, 63.3, 120.0, 125.0, 129.2, 137.5, 170.0

1-bromo-N-phenylcyclobutane-1-carboxamide (1b)



IR (neat) v 3287, 2991, 1655, 1438, 1251, 752 cm⁻¹; ¹H NMR (CDCl₃) δ : 2.01-2.09 (m, 1H), 2.30-2.38 (m, 1H), 2.64-2.70 (m, 2H), 3.09-3.15 (m, 2H), 7.15 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 8.2 Hz, 2H), 7.55 (d, J = 8.6 Hz, 2H), 7.99 (s, 1H). ¹³C NMR (CDCl₃) δ : 17.2, 38.0, 60.7, 119.9, 124.9, 129.1, 137.5, 169.0; HRMS (EI-MS) calcd. for C₁₁H₁₃BrNO (M+H⁺): 254.0181; found 254.0181

1-bromo-N-phenylcyclopentane-1-carboxamide (1c)



IR (neat) v 3371, 2875, 1668, 1529, 1436, 747 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.90-1.97 (m, 2H), 2.00-2.07 (m, 2H), 2.32-2.36 (m, 2H), 2.52-2.58 (m, 2H), 7.15 (t, J = 7.4 Hz, 1H), 7.36 (t, J = 7.5 Hz, 2H),

7.56 (d, J = 8.6 Hz, 2H), 8.52 (s, 1H). ¹³C NMR (CDCl₃) δ : 24.0, 42.7, 74.4, 120.0, 124.9, 129.1, 137.5, 169.1; HRMS (EI-MS) calcd. for C₁₂H₁₅BrNO (M+H⁺): 268.0337; found 268.0337

1-bromo-N-phenylcyclohexane-1-carboxamide (1d)



IR (neat) v 3311, 2934, 1649, 1536, 1441, 1119, 750 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.32-1.41 (m, 1H), 1.69-1.85 (m, 5H), 2.14-2.25 (m, 4H), 7.15 (t, J = 7.4 Hz, 1H), 7.36 (t, J = 8.6 Hz, 2H), 7.55 (d, J = 8.7 Hz, 2H), 8.37 (s, 1H). ¹³C NMR (CDCl₃) δ : 22.9, 24.8, 31.0, 38.2, 120.1, 124.9, 129.2, 137.6, 169.8; HRMS (EI-MS) calcd. for C₁₃H₁₇BrNO (M+H⁺): 282.0494; found 282.0494

methyl 4-(2-bromo-2-methylpropanamido)benzoate (1e)



IR (neat) v 3341, 2948, 1684, 1524, 1170, 1100, 772 cm⁻¹; ¹H NMR (CDCl₃) δ : 2.06 (s, 6H), 3.91 (s, 3H), 7.64 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 8.59 (s, 1H). ¹³C NMR (CDCl₃) δ : 32.6, 52.2, 62.9, 119.1, 126.3, 130.9, 141.6, 166.6, 170.3; HRMS (EI-MS) calcd. for C₁₂H₁₅BrNO₃ (M+H⁺): 300.0235; found 300.0236

4-bromophenyl-2-bromo-2-methylpropanamide (1f)



IR (neat) v 3310, 2983, 1659, 1485, 1109, 819 cm⁻¹; ¹H NMR (CDCl₃) δ : 2.04 (s, 6H), 7.43-7.48 (m, 4H), 8.44 (s, 1H). ¹³C NMR (CDCl₃) δ : 32.6, 63.1, 117.7, 121.6, 132.1, 136.6, 170.1; HRMS (EI-MS) calcd. for C₁₀H₁₂Br₂NO (M+H⁺): 319.9286; found 319.9287

4-chlorophenyl-2-bromo-2-methylpropanamide (1g)



IR (neat) v 3328, 2930, 1637, 1527, 1106, 825 cm⁻¹; ¹H NMR (CDCl₃) δ : 2.04 (s, 6H), 7.32 (d, *J* = 8.8 Hz, 2H), 7.50 (d, *J* = 8.8 Hz, 2H), 8.45 (s, 1H). ¹³C NMR (CDCl₃) δ : 32.6, 63.1, 121.3, 129.2, 130.0, 136.0, 170.1; HRMS (EI-MS) calcd. for C₁₀H₁₂BrClNO (M+H⁺): 275.9791; found 275.9792

2-bromo-N-(3-methoxyphenyl)-2-methylpropanamide (1h)



IR (neat) v 3290, 2931, 1655, 1447, 1276, 1032, 788 cm⁻¹; ¹H NMR (CDCl₃) δ : 2.05 (s, 6H), 3.82 (s, 3H), 6.70 (dd, J = 2.5 and 8.4 Hz, 1H), 7.00 (dd, J = 2.0, and 8.0 Hz, 1H), 7.24 (t, J = 8.2, 1H), 7.32 (t, J = 2.3 Hz, 1H), 8.44 (s, 1H). ¹³C NMR (CDCl₃) δ : 32.6, 55.4, 63.2, 105.4, 111.0, 112.0, 129.8, 138.7, 160.3, 170.1; HRMS (EI-MS) calcd. for C₁₁H₁₅BrNO₂ (M+H⁺): 272.0286; found 272.0286

N-benzyl-2-bromo-2-methylpropanamide (1i)



¹H NMR (CDCl₃) δ: 2.00 (s, 6H), 4.46 (d, *J* = 5.7 Hz, 2H), 7.00 (s, 1H), 7.27-7.32 (m, 3H), 7.34-7.38 (m, 2H). ¹³C NMR (CDCl₃) δ: 32.7, 44.5, 63.1, 127.6, 127.7, 128.9, 137.8, 172.0

2-bromo-N-cyclohexyl-2-methylpropanamide (1j)



IR (neat) v 3329, 2930, 2850, 1636, 1528, 1105, 891 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.17-1.24 (m, 3H), 1.34-1.42 (m, 2H), 1.58-1.64 (m, 1H), 1.69-1.74 (m, 2H), 1.89-1.93 (m, 2H), 1.94 (s, 6H), 3.66-3.74 (m, 1H), 6.60 (s, 1H). ¹³C NMR (CDCl₃) δ : 24.7, 25.6, 32.7, 32.7, 49.1, 63.9, 171.1; HRMS (EI-MS) calcd. for C₁₀H₁₉BrNO (M+H⁺): 248.0650; found 248.0652

2-bromo-N-(tert-butyl)-2-methylpropanamide (1k)

¹H NMR (CDCl₃) δ: 1.37 (s, 9H), 1.92 (s, 6H), 6.57 (s, 1H). ¹³C NMR (CDCl₃) δ: 28.4, 32.6, 51.7, 64.0, 171.3

2-bromo-N-(3,5-dimethoxyphenyl)-2-methylpropanamide (11)



¹H NMR (CDCl₃) δ : 2.04 (s, 6H), 3.79 (s, 6H), 6.27 (t, *J* = 2.2 Hz, 1H), 6.78 (d, *J* = 2.2 Hz, 2H), 8.40 (s, 1H). ¹³C NMR (CDCl₃) δ : 32.6, 55.5, 3.2, 97.6, 98.1, 139.2, 161.2, 170.1

Styrene derivatives (2) were synthesized by Wittig reactions.

^tBuOK (2 equiv) was added to THF solution of ethyltriphenylphosphonium bromide (2 equiv) at 0 °C and the resulting solution was stirred for several hours. After stirring, aldehyde (1 equiv) was added to the mixture. The resulting mixture vigorously stirred overnight at room temperature. After this time, the contents of the flask were washed with brine, and extracted with EtOAc. The combined organic layer was dried over MgSO₄ and evaporated. The crude residue was purified by flash chromatography, eluting hexane-EtOAc to afford the product **2**.

N,N-dimethyl-4-(prop-1-en-1-yl)aniline (E: Z = 23:77) (2a)



¹H NMR (CDCl₃) δ: 1.85 (dd, *J* = 1.6 and 6.7 Hz, 0.6H), 1.92 (dd, *J* = 1.7 and 7.1 Hz, 2.4H), 2.94 (s, 1.2H), 2.96 (s, 4.8H), 5.62 (dq, *J* = 7.1 and 11.4 Hz, 0.8H), 6.03 (dq, *J* = 6.6 and 15.6 Hz, 0.2H), 6.30-6.36 (m, 1H), 6.67 (d, *J* = 8.9 Hz, 0.4H), 6.72 (d, *J* = 9.0 Hz, 1.6H), 7.21-7.25 (m, 2H). ¹³C NMR (CDCl₃) δ: 14.8, 18.5, 40.5, 40.5, 112.1, 112.6, 121.2, 123.3, 126.2, 126.7, 126.7, 129.7, 129.8, 130.8, 149.1, 149.6

N,*N*-diethyl-4-(prop-1-en-1-yl)aniline (E : Z = 22 : 78) (2b)



¹H NMR (CDCl₃) δ : 1.17 (t, *J* = 7.0 Hz, 6H), 1.84 (dd, *J* = 1.8 and 6.6 Hz, 0.7H), 1.92 (d, *J* = 1.7 and 7.1 Hz, 2.3H), 3.36 (q, *J* = 7.0 Hz, 4H), 5.58 (dq, *J* = 7.2 and 11.6 Hz, 0.8H), 5.99 (dq, *J* = 6.6 and 15.6 Hz, 0.2H), 6.29-6.33 (m, 1H), 6.61 (d, *J* = 8.0 Hz, 0.5H), 6.66 (d, *J* = 8.5 Hz, 1.5H), 7.19-7.22 (m, 2H). ¹³C NMR (CDCl₃) δ : 12.7, 14.8, 18.5, 44.4, 111.4, 111.9, 120.7, 122.8, 125.2, 125.7, 126.9, 129.7, 130.1, 130.8, 146.3, 146.8

4-(4-(prop-1-en-1-yl)phenyl)morpholine (E : Z = 21 : 79) (2c)



¹H NMR (CDCl₃) δ : 1.85 (dd, J = 1.6 and 6.5 Hz, 0.6H), 1.90 (dd, J = 1.8 and 7.0 Hz, 2.4H), 3.15 (t, J = 4.8 Hz, 1H), 3.16 (t, J = 4.9 Hz, 3H), 3.84-3.87 (m, 4H), 5.67 (dq, J = 7.2 and 11.6 Hz, 0.7H), 6.09 (dq, J = 6.6 and 15.7Hz, 0.2H), 6.31-6.35 (m, 1H), 6.84 (d, J = 8.7 Hz, 0.4H), 6.88 (d, J = 8.8 Hz, 1.6H), 7.24 (d, J = 8.6 Hz, 2H). ¹³C NMR (CDCl₃) δ : 14.8, 18.5, 49.3, 49.4, 67.0, 115.2, 115.7, 123.2, 124.9, 126.7, 129.4, 129.6, 129.9, 130.1, 130.5, 149.7, 150.2

1-(4-(prop-1-en-1-yl)phenyl)pyrrolidine (E : Z = 17 : 83) (2d)



¹H NMR (CDCl₃) δ: 1.84 (dd, J = 1.5 and 6.5 Hz, 0.5H), 1.91 (dd, J = 1.8 and 7.1 Hz, 2.4H), 1.99-2.04 (m, 4H), 3.27-3.34 (m, 4H), 5.58 (dq, J = 7.2 and 11.6 Hz, 0.8H), 6.01 (dq, J = 6.6 and 15.6 Hz, 0.2H), 6.29-6.37 (m, 1H), 6.50 (d, J = 8.0 Hz, 0.4H), 6.54 (d, J = 8.5 Hz, 1.6H), 7.21-7.23 (m, 2H). ¹³C NMR (CDCl₃) δ: 14.8, 18.5, 25.5, 47.7, 111.3, 111.7, 120.6, 122.8, 125.2, 126.8, 130.0, 131.0, 146.6 9-ethyl-3-(prop-1-en-1-yl)-9H-carbazole (E : Z = 30 : 70) (2e)



¹H NMR (CDCl₃) δ : 1.45 (t, *J* = 7.3 Hz, 3H), 1.94 (dd, *J* = 1.7 and 6.6 Hz, 0.9H), 2.02 (dd, *J* = 1.8 and 7.1 Hz, 2H), 4.33-4.40 (m, 2H), 5.79 (dq, *J* = 7.1 and 11.5 Hz, 0.7H), 6.26 (dq, *J* = 6.6 and 15.6 Hz, 0.3H), 6.59-6.66 (m, 1H), 7.21-7.25 (m, 1H), 7.32-7.51 (m, 4H), 8.06 (s, 1H), 8.09-8.12 (m, 1H). ¹³C NMR (CDCl₃) δ : 13.7, 14.8, 18.6, 21.0, 37.4, 60.3, 108.0, 108.4, 108.5, 117.8, 118.7, 118.8, 120.4, 120.6, 122.7, 122.8, 123.0, 123.1, 123.8, 124.5, 125.6, 125.6, 127.0, 128.6, 129.2, 130.6, 131.7, 138.6, 139.2, 140.2

N,*N*-dimethyl-4-(but-1-en-1-yl)aniline (E : Z = 13 : 87) (2f)



IR (neat) v 2959, 2871, 1608, 1518, 1347, 1161, 946, 824 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.08-1.12 (m, 3H), 2.23 (dquin, J = 1.6 and 7.4 Hz, 0.2H), 2.40 (dquin, J = 1.9 and 7.4 Hz, 1.8H), 2.96 (s, 0.7H), 2.98 (s, 5.3H), 5.50 (dt, J = 7.2 and 11.4 Hz, 0.9H), 6.09 (dt, J = 6.5 and 15.7 Hz, 0.1H), 6.30-6.34 (m, 1H), 6.70-6.75 (m, 2H), 7.23-7.28 (m, 2H). ¹³C NMR (CDCl₃) δ : 14.0, 14.7, 22.1, 26.1, 40.4, 40.5, 112.1, 112.6, 126.3, 126.7, 128.2, 128.7, 129.7, 131.3, 149.1, 149.6; HRMS (EI-MS) calcd. for C₁₂H₁₈N (M+H⁺): 176.1439; found 176.1440

N,N-dimethyl-4-(pent-1-en-1-yl)aniline (E: Z = 12:88) (2g)



¹H NMR (CDCl₃) δ : 0.97 (t, *J* = 7.4 Hz, 3H), 1.49 (sext, *J* = 7.3 Hz, 2H), 2.15-2.19 (m, 0.2H), 2.33-2.38 (m, 1.8H), 2.95 (s, 2H), 2.97 (s, 6H), 5.50 (dt, *J* = 7.2 and 11.6 Hz, 0.9 H), 6.04 (dt, *J* = 6.6 and 15.6 Hz, 0.1 H), 6.29-6.34 (m, 1H), 6.69-6.73 (m, 2H), 7.22-7.26 (m, 2H). ¹³C NMR (CDCl₃) δ : 13.8, 14.0, 22.9, 23.4, 31.0, 35.3, 40.7, 40.8, 112.3, 112.8, 126.6, 126.8, 126.0, 126.8, 127.0, 128.8, 129.9, 130.0, 148.2, 148.7

4-(but-2-en-2-yl)-*N*,*N*-dimethylaniline (*E* : *Z* = 15 : 85) (**2h**)

IR (neat) v 2961, 2796, 1609, 1519, 1345, 1165, 946, 823 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.65 (d, *J* = 6.8 Hz, 2.5H), 1.78 (d, *J* = 6.8 Hz, 0.5H), 2.00-2.02 (m, 3H), 2.94 (s, 1H), 2.96 (s, 5H), 5.48 (dq, *J* = 1.3 and 6.8 Hz, 0.8H), 5.76 (dq, *J* = 1.3 and 6.7 Hz, 0.1H), 6.71 (d, *J* = 8.9 Hz, 0.4H), 6.72 (d, *J* = 8.7 Hz, 2H), 7.13 (d, *J* = 8.6 Hz, 1.6H), 7.29 (d, *J* = 8.8 Hz, 0.3H). ¹³C NMR (CDCl₃) δ :14.3, 15.1, 15.4, 25.4, 40.6, 40.7, 112.1, 112.5, 119.2, 120.3, 123.2, 128.9, 129.9, 136.4, 149.2; HRMS (EI-MS) calcd. for C₁₂H₁₈N (M+H⁺): 176.1439; found 176.1439

2. General procedure

General procedure for the synthesis of 3.

Substrate 1 (0.50 mmol), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv) and L13 (16.8 mg, 0.025 mmol, 0.05 equiv) were sequentially added under air to a drum vial equipped with a stir bar and a screw cap. After flashing nitrogen gas (purity 99.95%), dried 1,4-dioxane (1.0 mL), i Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv) and substrate **2** (1.00 mmol, 2.0 equiv) were added by syringe and the resulting mixture was vigorously stirred under nitrogen atmosphere for 24 h at 110 °C. After this time, the contents of the flask were filtered through the plug of silica gel, and then concentrated by rotary evaporation. The residue was purified by flash chromatography, eluting hexane/EtOAc to afford the product **3**.

5-(4-(dimethylamino)phenyl)-3,3,4-trimethyl-1-phenylpyrrolidin-2-one (3a)



Following the general procedure above, using **1a** (121.4 mg, 0.50 mmol), styrene **2a** (0.17 mL, 1.00 mmol, 2.0 equiv, E : Z = 23 : 77), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3a** (132.2 mg, 82%); IR (neat) v 3316, 2968, 2871, 1780, 1686, 1617, 1521, 1354, 1175, 948, 804, 753 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.00 (d, J = 6.8 Hz, 3H), 1.10 (s, 3H), 1.29 (s, 3H), 1.93-1.99 (m, 1H), 2.88 (s, 6H), 4.53 (d, J = 9.4 Hz, 1H), 6.59 (d, J = 8.6 Hz, 2H), 7.00 (t, J = 7.4 Hz, 1H), 7.03 (d, J = 8.6 Hz, 2H), 7.19 (t, J = 8.6 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H). ¹³C NMR (CDCl₃) δ : 10.3, 19.0, 23.9, 40.5, 44.0, 49.2, 67.3, 112.4, 123.4, 124.7, 126.6, 128.1, 128.3, 138.3, 150.0, 179.9; HRMS (EI-MS) calcd. for C₂₁H₂₇N₂O (M+H⁺): 323.2123; found 323.2124

7-(4-(diethylamino)phenyl)-8-methyl-6-phenyl-6-azaspiro[3.4]octan-5-one (3b)



Following the general procedure above, using **2b** (127.1 mg, 0.50 mmol), styrene **2b** (0.20 mL, 1.00 mmol, 2.0 equiv, E : Z = 22 : 78), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3b** (144.7 mg, 80%); IR (neat) v 2968, 2109, 1686, 1518, 1352, 1265, 1187, 1154, 1079, 801 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.10 (t, J = 7.1 Hz, 6H), 1.20 (d, J = 6.9 Hz, 3H), 1.82-1.91 (m, 2H), 2.05-2.28 (m, 4H), 2.58-2.66 (m, 1H), 3.26 (q, J = 6.9 Hz, 4H), 4.47 (d, J = 6.9 Hz, 1H), 6.52 (d, J = 8.7 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 7.00 (t, J = 7.4 Hz, 1H), 7.21 (t, J = 8.2 Hz, 2H), 7.39 (d, J = 8.2 Hz, 2H). ¹³C NMR (CDCl₃) δ : 12.7, 13.0, 16.6, 24.9, 29.4, 44.2, 47.2, 50.1, 67.9, 111.6, 122.7, 124.4, 126.0, 127.8, 128.4, 138.7, 147.3, 178.8; HRMS (EI-MS) calcd. for C₂₄H₃₁N₂O (M+H⁺): 363.2436; found 363.2436

3-(4-(diethylamino)phenyl)-4-methyl-2-phenyl-2-azaspiro[4.4]nonan-1-one (3c)



Following the general procedure above, using **1c** (134.1 mg, 0.50 mmol), styrene **2b** (0.20 mL, 1.00 mmol, 2.0 equiv, E : Z = 22 : 78), FeCl₂ (3.1 mg, 0.025 mmol, 0.05 equiv), L13 (16.8 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3c** (87.3 mg, 46%); IR (neat) v 2963, 2086, 1685, 1518, 1352, 1188, 1071, 800, 689 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.02 (d, J = 6.8 Hz, 3H), 1.10 (t, J = 7.0 Hz, 6H), 1.48-1.54 (m, 1H), 1.63-1.73 (m, 2H), 1.82-1.96 (m, 4H), 2.04-2.10 (m, 1H), 2.32-2.37 (m, 1H), 3.26 (q, J = 7.0 Hz, 4H), 4.50 (d, J = 8.8 Hz, 1H), 6.52 (d, J = 8.7 Hz, 2H), 6.98-7.01 (m, 3H), 7.20 (t, J = 8.0 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H). ¹³C NMR (CDCl₃) δ : 11.6, 12.6, 26.3, 26.5, 30.6, 35.6, 44.2, 48.5, 54.5, 68.0, 111.5, 123.1, 124.4, 125.5, 128.1, 128.3, 138.5, 147.3, 180.7; HRMS (EI-MS) calcd. for C₂₅H₃₃N₂O (M+H⁺): 377.2593; found 377.2593

3-(4-(dimethylamino)phenyl)-4-methyl-2-phenyl-2-azaspiro[4.5]decan-1-one (3d)



Following the general procedure above, using **1d** (128.1 mg, 0.50 mmol), styrene **2a** (0.20 mL, 1.00 mmol, 2.0 equiv, E : Z = 23 : 77), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3d** (71.4 mg, 39%); IR (neat) v 2926, 2364, 1688, 1356, 1201, 1081, 800, 742, 689 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.03 (d, J = 6.9 Hz, 3H), 1.25-1.32 (m, 1H), 1.44-1.56 (m, 4H), 1.67-1.76 (m, 3H), 1.84-1.96 (m, 2H), 2.26-2.33 (m, 1H), 2.88 (s, 6H), 4.57 (d, J = 8.8 Hz, 1H), 6.58 (d, J = 8.9 Hz, 2H), 6.99 (t, J = 7.4 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 7.19 (t, J = 8.0 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H). ¹³C NMR (CDCl₃) δ : 11.6, 21.7, 22.1, 25.9, 28.1, 33.8, 40.5, 45.9, 49.4, 67.0, 112.4, 123.2, 124.5, 127.3, 127.9, 128.3, 138.4, 149.9, 179.3; HRMS (EI-MS) calcd. for C₂₄H₃₁N₂O (M+H⁺): 363.2436; found 363.2436

methyl 4-(5-(4-(dimethylamino)phenyl)-3,3,4-trimethyl-2-oxopyrrolidin-1-yl)benzoate (3e)



Following the general procedure above, using **1e** (150.4 mg, 0.50 mmol), styrene **2a** (0.17 mL, 1.00 mmol, 2.0 equiv, E : Z = 23 : 77), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.8 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3e** (149.9 mg, 79%); IR (neat) v 3303, 2956, 2110, 1697, 1603, 1523, 1351, 1275, 1176, 1108, 794, 762, 697 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.00 (d, J = 6.8 Hz, 3H), 1.09 (s, 3H), 1.29 (s, 3H), 1.93-1.99 (m, 1H), 2.87 (s, 6H), 3.81 (s, 3H), 4.56 (d, J = 9.4 Hz, 1H), 6.56 (d, J = 8.7 Hz, 2H), 7.00 (d, J = 8.7 Hz, 2H), 7.41 (d, J = 8.7 Hz, 2H), 7.86 (d, J = 8.8 Hz, 2H). ¹³C NMR (CDCl₃) δ : 10.3, 19.0, 23.8, 40.4, 44.2, 49.1, 52.0, 67.1, 112.4, 122.4, 125.6, 126.0, 127.9, 129.9, 142.5, 150.1, 166.8,

1-(4-bromophenyl)-3,3,4-trimethyl-5-(4-morpholinophenyl)pyrrolidin-2-one (3f)



Following the general procedure above, using **1f** (160.5 mg, 0.50 mmol), styrene **2e** (0.19 mL, 1.00 mmol, 2.0 equiv, E : Z = 21 : 79), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3f** (188.5 mg, 85%); IR (neat) v 2961, 2855, 1693, 1488, 1348, 1222, 1113, 924, 822, 726 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.98 (d, J = 6.8 Hz, 3H), 1.08 (s, 3H), 1.27 (s, 3H), 1.93 (dq, J = 6.8 and 9.4 Hz, 1H), 3.10-3.11 (m, 4H), 3.80-3.82 (m, 4H), 4.51 (d, J = 9.4 Hz, 1H), 6.78 (d, J = 8.2 Hz, 2H), 7.04 (d, J = 8.6 Hz, 2H), 7.17 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 8.8 Hz, 2H). ¹³C NMR (CDCl₃) δ : 10.2, 18.9, 23.7, 44.0, 49.0, 49.1, 66.8, 67.0, 115.6, 117.7, 124.7, 128.0, 131.4, 131.9, 137.1, 150.6, 179.8; HRMS (EI-MS) calcd. for C₂₃H₂₈N₂O₂ (M+H⁺): 443.1334; found 443.1333

1-(4-chlorophenyl)-3,3,4-trimethyl-5-(4-(pyrrolidin-1-yl)phenyl)pyrrolidin-2-one (3g)



Following the general procedure above, using **1g** (138.4 mg, 0.50 mmol), styrene **2d** (0.18 mL, 1.00 mmol, 2.0 equiv, E : Z = 17 : 83), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3g** (138.6 mg, 72%); IR (neat) v 2961, 2094, 1686, 1524, 1491, 1366, 1185, 1079,

833, 792 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.98 (d, *J* = 6.8 Hz, 3H), 1.08 (s, 3H), 1.28 (s, 3H), 1.91-1.98 (m, 5H), 3.21 (t, *J* = 6.5 Hz, 4H), 4.47 (d, *J* = 9.4 Hz, 1H), 6.42 (d, *J* = 8.5 Hz, 2H), 6.98 (d, *J* = 8.5 Hz, 2H), 7.14 (d, *J* = 8.9 Hz, 2H), 7.24 (d, *J* = 8.9 Hz, 2H). ¹³C NMR (CDCl₃) δ : 10.2, 18.9, 23.8, 25.5, 44.0, 47.5, 49.2, 67.4, 111.6, 124.5, 124.8, 128.2, 128.4, 129.8, 136.8, 147.5, 179.9; HRMS (EI-MS) calcd. for C₂₃H₂₈ClN₂O (M+H⁺): 383.1890; found 383.1890

5-(9-ethyl-9H-carbazol-3-yl)-1-(3-methoxyphenyl)-3,3,4-trimethylpyrrolidin-2-one (3h)



Following the general procedure above, using **1h** (136.2 mg, 0.50 mmol), styrene **2e** (0.20 mL, 1.00 mmol, 2.0 equiv, E : Z = 30 : 70), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.8 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3h** (157.9 mg, 74%); IR (neat) v 3555, 2959, 1707, 1688, 1604, 1491, 1345, 1231, 1050, 774, 755, 687 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.04 (d, J = 6.5 Hz, 3H), 1.15 (s, 3H), 1.34 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H), 2.06-2.12 (m, 1H), 3.67 (s, 3H), 4.28 (q, J = 7.2 Hz, 2H), 4.79 (d, J = 9.1 Hz, 1H), 6.49 (d, J = 8.1 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 7.01 (t, J = 8.1 Hz, 1H), 7.10 (s, 1H), 7.21 (t, J = 7.3 Hz, 1H), 7.25 (d, J = 6.8 Hz, 2H), 7.36 (d, J = 8.1 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.93 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H). ¹³C NMR (CDCl₃) δ : 10.3, 13.9, 19.1, 23.9, 37.7, 44.2, 49.6, 55.2, 68.2, 108.6, 108.8, 109.2, 110.7, 115.4, 118.9, 119.4, 120.4, 122.5, 122.9, 124.4, 125.9, 128.9, 129.8, 139.4, 139.6, 140.3, 159.5, 180.1; HRMS (EI-MS) calcd. for C₂₈H₃₁N₂O₂ (M+H⁺): 427.2386; found 427.2387

1-benzyl-5-(4-(diethylamino)phenyl)-3,3,4-trimethylpyrrolidin-2-one (3i)



Following the general procedure above, using **1i** (128.1 mg, 0.50 mmol), styrene **2b** (0.20 mL, 1.00 mmol, 2.0 equiv, E : Z = 22 : 78), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol,

0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3i** (139.8 mg, 77%); IR (neat) v 3358, 2966, 1682, 1518, 1399, 1357, 1263, 1195, 1075, 803, 697 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.81 (d, *J* = 6.9 Hz, 3H), 0.94 (s, 3H), 1.19 (t, *J* = 7.0 Hz, 6H), 1.23 (s, 3H), 1.85-1.91 (m, 1H), 3.37 (q, *J* = 7.0 Hz, 4H), 3.45 (d, *J* = 14.3 Hz, 1H), 3.60 (d, *J* = 9.4 Hz, 1H), 5.03 (d, *J* = 14.3 Hz, 1H), 6.64 (d, *J* = 8.8 Hz, 2H), 6.92 (d, *J* = 8.6 Hz, 2H), 7.00 (dd, *J* = 2.4 and 7.6 Hz, 2H), 7.21-7.25 (m, 3H). ¹³C NMR (CDCl₃) δ : 10.3, 12.7, 18.6, 23.5, 43.3, 44.1, 44.4, 48.7, 65.3, 111.7, 124.4, 127.3, 128.4, 128.7, 129.0, 137.1, 147.8, 180.5; HRMS (EI-MS) calcd. for C₂₄H₃₃N₂O (M+H⁺): 365.2593; found 365.2593

1-cyclohexyl-5-(4-(diethylamino)phenyl)-3,3,4-trimethylpyrrolidin-2-one (3j)



Following the general procedure above, using **1j** (124.1 mg, 0.50 mmol), styrene **2b** (0.20 mL, 1.00 mmol, 2.0 equiv, E : Z = 22 : 78), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.8 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3j** (105.6 mg, 59%); IR (neat) v 2962, 2856, 1678, 1518, 1356, 1265, 1075, 798 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.83 (d, J = 6.8 Hz, 3H), 0.94 (s, 3H), 0.95-1.01 (m, 1H), 1.05-1.13 (m, 2H), 1.16 (s, 3H), 1.17 (t, J = 7.1 Hz, 6H), 1.36 (dq, J = 3.5 and 12.4 Hz, 1H), 1.48 (t, J = 12.7 Hz, 2H), 1.59-1.67 (m, 3H), 1.80 (dq, J = 6.9 and 9.3 Hz, 1H), 1.97 (dq, J = 3.2 and 12.0 Hz, 1H), 3.23 (t, J = 12.0 Hz, 1H), 3.35 (q, J = 7.0 Hz, 4H), 3.86 (d, J = 9.3 Hz, 1H), 6.63 (d, J = 8.7 Hz, 2H), ¹³C NMR (CDCl₃) δ : 10.4, 12.7, 18.8, 23.7, 25.5, 26.0, 26.3, 29.8, 30.1, 43.3, 44.4, 48.9, 54.3, 66.8, 111.6, 126.8, 128.9, 147.7, 181.2; HRMS (EI-MS) calcd. for C₂₃H₃₇N₂O (M+H⁺): 357.2906; found 357.2904

1-(tert-butyl)-5-(4-(dimethylamino)phenyl)-3,3,4-trimethylpyrrolidin-2-one (3k)



Following the general procedure above, using **1k** (111.2 mg, 0.50 mmol), styrene **2b** (0.20 mL, 1.00 mmol, 2.0 equiv, E : Z = 23 : 77), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (17.0 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3k** (65.3 mg, 40%); IR (neat) v 2958, 1672, 1613, 1519, 1387, 1348, 1195, 790 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.87 (d, J = 6.9 Hz, 3H), 0.94 (s, 3H), 1.11 (s, 3H), 1.16 (t, J = 7.0 Hz, 6H), 1.25 (s, 9H), 1.68-1.74 (m, 1H), 3.34 (q, J = 7.0 Hz, 4H), 4.00 (d, J = 8.1 Hz, 1H), 6.62 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 8.3 Hz, 2H). ¹³C NMR (CDCl₃) δ : 11.0, 12.7, 19.6, 23.8, 28.7, 43.6, 44.4, 49.3, 55.7, 67.4, 111.7, 127.6, 131.8, 147.2, 182.3; HRMS (EI-MS) calcd. for C₂₁H₃₅N₂O (M+H⁺): 331.2749; found 331.2749

5-(4-(dimethylamino)phenyl)-4-ethyl-3,3-dimethyl-1-phenylpyrrolidin-2-one (31)



Following the general procedure above, using **1a** (121.1 mg, 0.50 mmol), styrene **2f** (0.18 mL, 1.00 mmol, 2.0 equiv, E : Z = 13 : 87), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3m** (109.1 mg, 65%); IR (neat) v 2965, 2929, 1876, 1696, 1524, 1348, 1171, 1114, 813, 791, 754, 691 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.85 (t, J = 7.5 Hz, 3H), 1.15 (s, 3H), 1.39 (s, 3H), 1.52-1.59 (m, 2H), 1.86-1.90 (m, 1H), 2.88 (s, 6H), 4.53 (d, J = 9.1 Hz, 1H), 6.57 (d, J = 8.7 Hz, 2H), 6.99 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 8.5 Hz, 2H), 7.18 (t, J = 8.4 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H). ¹³C NMR (CDCl₃) δ : 13.2, 19.0, 20.7, 25.7, 40.5, 44.1, 55.5, 66.6, 112.3, 123.7, 124.8, 127.2, 128.3, 128.5, 138.2, 149.9, 179.8; HRMS (EI-MS) calcd. for C₂₂H₂₉N₂O (M+H⁺): 337.2280; found 337.2280

1-(4-chlorophenyl)-5-(4-(dimethylamino)phenyl)-3,3-dimethyl-4-propylpyrrolidin-2-one (3m)



Following the general procedure above, using **1g** (138.4 mg, 0.50 mmol), styrene **2g** (0.18 mL, 1.00 mmol, 2.0 equiv, E : Z = 12 : 88), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3m** (114.9 mg, 60%); IR (neat) v 2965, 2931, 2868, 1684, 1528, 1359, 1172, 1083, 1013, 817, 780 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.80 (t, J = 7.3 Hz, 3H), 1.10-1.17 (m, 1H), 1.13 (s, 3H), 1.24-1.30 (m, 1H), 1.36 (s, 3H), 1.41-1.53 (m, 2H), 1.94-1.98 (m, 1H), 2.90 (s, 6H), 4.48 (d, J = 9.2 Hz, 1H), 6.57 (d, J = 8.7 Hz, 2H), 7.01 (d, J = 8.7 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 7.20 (d, J = 9.0 Hz, 2H). ¹³C NMR (CDCl₃) δ : 14.6, 19.0, 21.5, 25.4, 30.1, 40.4, 44.2, 53.5, 66.7, 112.3, 124.8, 126.5, 128.4, 128.5, 129.9, 136.7, 150.0, 179.8; HRMS (EI-MS) calcd. for C₂₃H₃₀ClN₂O (M+H⁺): 385.2047; found 385.2047

1-(3,5-dimethoxyphenyl)-5-(4-(dimethylamino)phenyl)-3,3,4-trimethylpyrrolidin-2-one (3n)



Following the general procedure above, using **11** (136.2 mg, 0.50 mmol), styrene **2a** (0.17 mL, 1.00 mmol, 2.0 equiv, E : Z = 23 : 77), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), ligand (16.8 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3n** (160.6 mg, 84%); IR (neat) v 3466, 2960, 1666, 1593, 1470, 1203, 1151, 1051, 831, 806, 685 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.98 (d, J = 6.8 Hz, 3H), 1.08 (s, 3H), 1.28 (s, 3H), 1.93 (dq, J = 6.8, and 9.3 Hz, 1H), 2.89 (s, 6H), 3.67 (s, 6H), 4.47 (d, J = 9.3 Hz, 1H), 6.13 (t, J

= 2.2 Hz, 1H), 6.54 (d, J = 2.2 Hz, 2H), 6.60 (d, J = 8.6 Hz, 2H), 7.04 (t, J = 8.7 Hz, 2H). ¹³C NMR (CDCl₃) δ : 10.3, 19.0, 23.8, 40.5, 44.2, 49.0, 55.4, 67.5, 97.6, 101.7, 112.6, 127.0, 127.9, 140.0, 150.1, 160.3, 180.1; HRMS (EI-MS) calcd. for C₂₃H₃₁N₂O₃ (M+H⁺): 383.2335; found 383.2335

5-(4-(dimethylamino)phenyl)-3,3,4,5-tetramethyl-1-phenylpyrrolidin-2-one (30)



Following the general procedure above, using **1a** (121.1 mg, 0.50 mmol), styrene **2h** (0.19 mL, 1.00 mmol, 2.0 equiv, E : Z = 15 : 85), FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv), L13 (16.9 mg, 0.025 mmol, 0.05 equiv), ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv), and dried 1,4-dioxane (1.00 mL) at 110 °C, yielded the product **3o** (48.4 mg, 29%); IR (neat) v 3351, 2969, 1685, 1520, 1351, 1198, 1130, 798, 754, 692 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.93 (d, J = 7.2 Hz, 3H), 1.26 (s, 3H), 1.33 (s, 3H), 1.57 (s, 3H), 2.48 (q, J = 7.5 Hz, 1H), 2.95 (s, 6H), 6.65 (d, J = 8.9 Hz, 2H), 6.96-6.97 (m, 2H), 7.12 (d, J = 7.3 Hz, 1H), 7.16-7.19 (m, 2H), 7.23 (d, J = 8.9 Hz, 2H). ¹³C NMR (CDCl₃) δ : 8.8, 19.8, 21.5, 26.7, 40.5, 42.8, 52.1, 68.4, 111.8, 126.7, 127.8, 128.1, 128.5, 132.8, 137.8, 149.5, 180.7; HRMS (EI-MS) calcd. for C₂₂H₂₉N₂O (M+H⁺): 337.2280; found 337.2280

3. Control experiments

#1: Radical inhibitor test

Substrate **1a** (0.50 mmol), substrate **2a** (1.00 mmol, 2.0 equiv), radical inhibitor (TEMPO : 78.1 mg, 0.5 mmol, 1.0 equiv, BHT : 110.2 mg, 0.5 mmol, 1.0 equiv) and FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv) were sequentially added under air to a drum vial equipped with a stir bar and a screw cap. After flashing nitrogen gas (purity 99.95%), dried 1,4-dioxane (1.0 mL) and ${}^{i}Pr_{2}NEt$ (0.17 mL, 1.00 mmol, 2.0 equiv) were added by syringe and the resulting mixture was vigorously stirred under nitrogen atmosphere for 24 h at 110 °C. After this time, the contents of the flask were checked by GC-MS.

#2: Cation trapping test



Substrate **1a** (0.50 mmol), substrate **2a** (1.00 mmol, 2.0 equiv), BnOH (0.26 mL, 2.5 mmol, 5 equiv) and FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv) were sequentially added under air to a drum vial equipped with a stir bar and a screw cap. After flashing nitrogen gas (purity 99.95%), dried 1,4-dioxane (1.0 mL) and ^{*i*}Pr₂NEt (0.17 mL, 1.00 mmol, 2.0 equiv) were added by syringe and the resulting mixture was vigorously stirred under nitrogen atmosphere for 24 h at 110 °C. After this time, the contents of the flask were filtered through the plug of silica gel. But desired product **3a-Nu** was not obtained.

#3: E-Z isomerization test for 2a

		FeCl ₂ (5 mo L13 (5 mol	1%) %)		
2a <i>E:Z</i> =22:78		<i>i</i> -Pr ₂ NEt (1 equiv.) 1,4-dioxane 110°C, time		2a E:Z	
time (h)	yield (%)	E:Z	time (h)	yield (%)	E:Z
0	-	22:78	6	>99	21:79
1 3	>99 >99	21:79 21:79	12 24	>99 >99	21:79 21:79

Substrate **2a** (161.2 mg, 1.0 mmol) and FeCl₂ (3.2 mg, 0.05 mmol, 0.05 equiv) were sequentially added under air to a drum vial equipped with a stir bar and a screw cap. After flashing nitrogen gas (purity 99.95%), dried 1,4-dioxane (1.0 mL) and ^{*i*}Pr₂NEt (0.17 mL, 1.0 mmol, 1.0 equiv) were added by syringe and the resulting mixture was vigorously stirred under nitrogen atmosphere for 1-24 h at 110 °C. After this time, the contents of the flask were filtered through the plug of silica gel, and then concentrated by rotary evaporation. The residue was purified by flash chromatography, eluting hexane/EtOAc to afford the product **2a**. *E/Z* ratios were determined by ¹H NMR analysis.

#4: Reactivities of Z- and E-2a



From *E*-2a

Substrate **1a** (121.1 mg, 0.50 mmol), substrate **2a** (0.17mL, 1.0 mmol, 2.0 equiv, E : Z = 100 : 0) and FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv) were sequentially added under air to a drum vial equipped with a stir bar and a screw cap. After flashing nitrogen gas (purity 99.95%), dried 1,4-dioxane (1.0 mL) and ^{*i*}Pr₂NEt (0.17 mL, 1.0 mmol, 2.0 equiv) were added by syringe and the resulting mixture

was vigorously stirred under nitrogen atmosphere for 1-24 h at 110 °C. After each reaction time, the yields were determined by ¹H NMR analysis.

From Z-2a

Substrate **1a** (121.1 mg, 0.50 mmol), substrate **2a** (0.17mL, 1.0 mmol, 2.0 equiv, E : Z = 0 : 100) and FeCl₂ (3.2 mg, 0.025 mmol, 0.05 equiv) were sequentially added under air to a drum vial equipped with a stir bar and a screw cap. After flashing nitrogen gas (purity 99.95%), dried 1,4-dioxane (1.0 mL) and ^{*i*}Pr₂NEt (0.17 mL, 1.0 mmol, 2.0 equiv) were added by syringe and the resulting mixture was vigorously stirred under nitrogen atmosphere for 1-24 h at 110 °C. After each reaction time, the yields were determined by ¹H NMR analysis.

4. Spectral charts for new compounds

¹H NMR (500 MHz, CDCl₃)



















210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 fl (ppm)





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm)























210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm)































